乳腺癌或去势抵抗性前列腺癌骨转移患者骨靶向药物4周与12周给药随机试验
该随机试验纳入263例乳腺癌或去势抵抗性前列腺癌骨转移患者,1:1分配至4周或12周骨靶向药物治疗一年。主要终点为健康相关生活质量-躯体功能(EORTC-QLQ-C30),非劣效界值5分。4周组躯体功能评分较12周组高1.2分(95%CI -1.6至4.0),达到非劣效;疼痛、整体健康状况、症状性骨骼事件率及无事件生存无显著差异。结论支持常用骨靶向药物降阶梯治疗是合理选择。
要点
- 12周给药在躯体功能方面非劣效于4周给药(差值1.2分,95%CI -1.6至4.0)。
- 疼痛、整体健康状况、症状性骨骼事件率及无事件生存两组无显著差异。
- 亚组分析(癌种、既往BTA使用、BTA类型)未见显著差异。
核心结论
- 在乳腺癌或去势抵抗性前列腺癌骨转移患者中,骨靶向药物12周给药在躯体功能方面非劣效于4周给药。
- 常用骨靶向药物降阶梯治疗是合理的治疗选择。
研究设计与样本
- 随机对照试验,1:1分配至4周或12周骨靶向药物治疗一年。
- 纳入263例乳腺癌(160例)或去势抵抗性前列腺癌(103例)骨转移患者,计划开始或已在接受骨靶向药物。
- 主要终点为EORTC-QLQ-C30躯体功能评分变化,非劣效界值5分,主要分析为符合方案集。
主要发现
- 4周组躯体功能评分较12周组高1.2分(95%CI -1.6至4.0),达到非劣效。
- 疼痛、整体健康状况、症状性骨骼事件率及无事件生存两组无显著差异。
- 亚组分析(癌种、既往BTA使用、BTA类型)未见显著差异。
关键数值与推荐
- 骨靶向药物包括地舒单抗(56.3%)、唑来膦酸(24.0%)和帕米膦酸(19.8%)。
- 非劣效界值为5分(EORTC-QLQ-C30躯体功能评分)。
临床怎么用
- 对于乳腺癌或去势抵抗性前列腺癌骨转移患者,可考虑将常用骨靶向药物从4周延长至12周给药。
- 降阶梯治疗需结合既往研究报告及系统综述综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal dosing of bone-targeted agents (BTAs), in patients with bone metastases remains an important clinical question. This trial compared 4-weekly versus 12-weekly therapy. PATIENTS AND METHODS: Patients with bone metastases from breast or castration-resistant prostate cancer (CRPC), who were going to start or already on BTAs, were randomised 1:1 to 4-weekly or 12-weekly BTA treatment for one year. Primary end point was change in health-related quality of life (HRQoL)-physical function European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30). Secondary end points included pain (EORTC-QLQ-BM22), global health status (EORTC-QLQ-C30), symptomatic skeletal events (SSEs) rates and time to SSEs. Primary analysis was per protocol and a non-inferiority margin of 5 points was used. RESULTS: Of 263 patients (160 breast cancer, 103 CRPC), 133 (50.6%) and 130 (49.4%) were randomised to the 4- and 12-weekly groups, respectively. BTAs included denosumab (56.3%), zoledronate (24.0%) and pamidronate (19.8%). Using repeated-measures analysis, across all time points, patients in the 4-weekly arm had a mean HRQL-physical subdomain score which was 1.2 (95% confidence interval: -1.6 to 4.0) higher than the 12-weekly arm. The study met the definition of non-inferiority for our primary outcome. Secondary outcomes showed no significant difference in scores for pain, global health status, SSE rates and SSE-free survival between arms. Subgroup analyses for cancer type, prior BTA use or BTA type showed no significant difference between arms. CONCLUSION: These results in addition to those previously reported for de-escalating zoledronate and systematic reviews in both breast and prostate cancers, would support that de-escalation of commonly used BTAs is a reasonable treatment option.
引用
- Clemons M, Ong M, Stober C, et al. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer. 2020. PMID: 33023785. doi:10.1016/j.ejca.2020.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。